Supernus Pharmaceuticals SUPN Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's stock issuance proceeds?
- Supernus Pharmaceuticals (SUPN) reported stock issuance proceeds of $13.67M in Q1 2026.
- How has Supernus Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Supernus Pharmaceuticals's stock issuance proceeds increased by 569.4% year-over-year, from $2.04M to $13.67M.
- What is the long-term trend for Supernus Pharmaceuticals's stock issuance proceeds?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's stock issuance proceeds has grown at a 51.7% compound annual growth rate (CAGR), from $7.1M to $37.62M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.